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ABSTRACT  
Colorectal cancer is a disease that originates from the neoplastic transformation of 
epithelial cells of the colon and rectum, as a result of the accumulation of genetic and 
epigenetic aberrations. At least four sequential genetic changes, affecting one oncogen 
(KRAS) and three tumor-suppressor genes (APC, SMAD4 and TP53), are required for 
the development of colorectal cancer. Abundant experimental studies and 
epidemiological data, as well as several human clinical trials suggest a protective effect 
of vitamin D against colon carcinogenesis. Hypercalcemia, a side effect of natural 
vitamin D, has currently restricted its therapeutic use; however, the development of new 
synthetic analogs with reduced hypercalcemic activity is promising for cancer therapy 
and prevention. Extensive research to elucidate the mechanisms underlying the anti-
cancer action of vitamin D is being undertaken. Understanding the complex molecular 
and cellular networks induced by vitamin D or its analogs will improve the use of these 
compounds for the prevention and treatment of colorectal cancer. 
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1 . INTRODUCTION. 
Colorectal cancer (CRC) is the fourth most common human malignant neoplasia 
worldwide, after lung, breast and prostate cancers, estimating 1 000 000 new cases 
(9.4% of total cancer cases) and 500 000 deaths annually. CRC prevalence is estimated 
in 2.8 million persons alive within 5 years of diagnosis, immediately after to that of 
breast cancer. The general incidence rates are higher in economically developed 
countries of North America, Australia, Eastern Asia, and Western Europe, whereas 
Africa, Latin America and Asia have a lower incidence. These variations in CRC 
incidence probably depend on different exposure to environmental and dietary factors. 
In this sense, migration studies have provided additional evidence by demonstrating that 
CRC incidence increases dramatically in populations moving from low to high-risk 
areas, suggesting that diets, life habits and other environmental conditions are major 
risk factors on CRC (Parkin et al., 2005). Accordingly, diets rich in fats and processed 
meat, and alcohol abuse increase the risk to suffer large bowel caner. Similarly, CRC is 
favored by low methionine and folate diets. Emerging evidence supports a protective 
effect of calcium and vitamin D in colorectal neoplasia (Lipkin et al., 1999).  
 
2. MOLECULAR GENETICS OF COLORECTAL CANCER.  
The molecular pathogenesis of colon cancer has been one of the most prominent 
research areas in the last years. The majority of the malignant colorectal tumors are 
sporadic, and only 5 to 10 percent are inherited as dominant autosomal. Familial 
Adenomatous Polyposis (FAP) and hereditary nonpolyposis Colorectal Cancer 
(HNPCC) are the two major forms of inherited CRC (Lynch & de la Chapelle, 2003). 
CRC is thought to be a result of a series of genetic mutations, which parallel 
histopathologic and molecular changes, from normal colonic epithelium to invasive 
carcinoma. Interestingly, the biological properties of the resulting tumor depend 
primarily on the temporary sequence of mutations rather than on the accumulation of 
these genetic alterations. 
Aberrant crypt foci (ACF) in the colorectal mucosa are considered the earliest 
morphological lesion in the development of colon neoplasia, and are currently classified 
as nondysplastic and dysplastic ACF. Generally, nondysplastic ACF, which harbor K-
RAS mutations, rarely lead to CRC. In contrast, dysplastic ACF contain mutations in the 
adenoma polyposis coli (APC) gene, and represent precursor lesions of colorectal 
adenomas and adenocarcinomas. Indeed, APC is considered the initiating “gatekeeper 
gene” in the majority of CRCs. The selective advantage acquired by the loss of APC 
function depends on the unregulated expression of the Wnt/β-catenin/T cell factor (Tcf) 
target genes, basically involved in cell-cell adhesion and cell cycle control. Fifty seven 
percent of the dysplastic ACF contain K-RAS mutations; thus, mutations in both APC 
and K-RAS genes are relevant early molecular events in the development of CRC. 
Subsequent disruption of the TGFβ signaling pathway by mutations in SMAD4, SMAD2 
or TGFBR2 genes, together with the altered Wnt signaling pathway, promotes a 
synergistic effect leading to a more malignant phenotype. Inactivation of the tumor 
suppressor gene TP53 is associated with adenoma-carcinoma transition in 50% of the 
CRC cases. Upon TP53 inactivation, cells lose cell cycle and mitotic checkpoints, 
accumulating mutations in other genes, which cooperate in promoting genomic 
instability and enhanced metastatic potential. This sequence of events resulting from 
APC and TP53 gene defects, account for 85% of sporadic CRC and 100% FAP patients, 
and is associated to chromosome instability (CIN), allelic loss and aneuploidy. 
Microsatellite instability (MIN) is a second type of genetic instability in CRC, and 
results from epigenetic silencing or mutations in the mismatch repair genes (MMR). 
Alterations in the MMR genes occur in 15% of sporadic and in all HNPCC patients. 
Interestingly, these CRC cases seem to follow a distinct genetic route, which does not 
result in bulk genomic aberrations and aneuploidy, although APC is likely involved 
(Fearon & Vogelstein, 1990; Fodde et al., 2001).  
 
3. VITAMIN D: POTENTIAL USE IN COLORECTAL CANCER PREVENTION 
AND THERAPY. 
1α,25-dihydroxy vitamin D3 or calcitriol [1α,25(OH)2D3], the most active 
molecular form of vitamin D, is synthesized from dietary-derived cholecalciferol, or 
from skin-derived precursors (7-dehydrocholesterol) through the action of UV sunlight. 
Most of the biological actions of 1α,25(OH)2D3 are transduced by the vitamin D 
receptor (VDR), which is a member of the nuclear receptor superfamily of ligand-
dependent transcription factors. VDR preferentially acts as a heterodimer with RXR 
(retinoid X receptor) through binding to specific genomic DNA sequences known as 
vitamin D response elements (VDRE), located at the regulatory regions of target genes. 
The interaction of 1α,25(OH)2D3 with VDR induces allosteric changes in its ligand- 
binding domain and enables the recruitment of co-activators. These co-activators 
comprise chromatin remodeling factors, histone acetylases (CBP/p300 and the p160 
coactivators), and proteins that interact directly with the basic transcription machinery 
(such as the Mediator-TRAP/DRIP complex). They are able to induce chromatin 
decondensation, RNA polymerase II recruitment and transcriptional activation (Aranda 
& Pascual, 2001). Although the main physiological role of 1α,25(OH)2D3 is the control 
of calcium homeostasis, however, compelling epidemiological, animal and molecular 
reports suggest novel activities of vitamin D. 
Numerous studies have provided indirect evidence for the relationship between 
low vitamin D status and the risk of CRC. One of the initial reports analyzed the 
geographic distribution of CRC deaths in the United States (U.S.), showing that CRC 
mortality rates were higher in the northern regions. Additional studies evidenced a high 
correlation between latitude and risk of CRC in the U.S. and Europe. It appears that 
people living at higher latitudes, presumably synthesize less vitamin D, and have a 
higher risk of dying from many common cancers including CRC. These observations 
closely parallel those which revealed that CRC mortality in the U.S. was higher in 
places where people were exposed to the lowest mean solar radiation, suggesting that 
vitamin D may play a protective role in CRC (Garland & Garland, 1980). Moreover, 
many epidemiologic studies show that high vitamin D intake and high plasma levels of 
25-hydroxycholecalciferol [25(OH)D3] are associated with a significant reduction of 
CRC incidence (Gorham et al., 2005; Grant & Garland, 2004; Holt et al., 2002). 
Experimental studies with rodent models of intestinal cancer suggest that 
vitamin D supply abrogates increased hyperproliferation and adenoma formation 
induced by stress diet (high fat, low calcium, high phosphate and low vitamin D) or 
carcinogen treatment (azoxymethane or 1,2-dimethylhydrazine). Treatment with 
vitamin D analogs in murine models of tumor xenografts elicited similar results. 
Moreover, administration of the synthetic vitamin D analogs Ro 25-6760 and EB1089 
to mice with HT-29 or LoVo tumor xenografts significantly inhibited tumor growth. 
Mice carrying a dominant mutation in the APC gene derived from ethylnitrosourea 
treatment (Apcmin) or mice with targeted mutations of the APC gene (Apc∆716, Apc1638) 
provide a well-defined model for spontaneous CRC initiation and FAP disorders. 
Apc1638 mice fed with a western-style diet (high-fat and phosphate, low in calcium and 
vitamin D) showed higher incidence of carcinomas and invasive tumors, demonstrating 
that diet modulates the incidence of carcinoma. Notably, intra-peritoneal treatment of 
Apcmin mice with vitamin D or a non-calcemic synthetic analog reduced tumor load by 
36%. Remarkably, wild type mice and rats fed with western-style diet for their entire 
life span will develop colon single-crypt dysplastic lesions and focal hyperplasias, 
indicative of tumorigenesis, which are prevented by increasing dietary calcium and 
vitamin D (Harris & Go, 2004).  
The previous data may suggest that VDR knockout animals should be prone to 
develop colon cancer. In fact, these animals exhibit high proliferating cell nuclear 
antigen activity, cyclin D1 expression, hyperproliferation and oxidative stress in the 
distal colon; however, they have normal colon cancer rates (Kallay et al., 2001).  
 
3.1. MECHANISMS OF VITAMIN D ACTION IN COLORECTAL CANCER. 
The anti-cancer activities exerted by 1α,25(OH)2D3 and its analogs in human 
colon cancer cells in vitro, are mediated by proliferation inhibition and induction of 
differentiation and apoptosis (Lamprecht & Lipkin, 2003). The anti-proliferative effect 
of vitamin D is attained by inducing G1 cell-cycle arrest, which is probably mediated by 
up-regulation of cell-cycle inhibitors, such as p21WAF1/CIP and p27KIP. Vitamin D 
modulates the activation of these cell cycle related genes by different mechanisms. p21 
contains a VDRE in its promoter region, and therefore is susceptible of direct 
transcriptional control by vitamin D. However, the induction of p27 expression, devoid 
of VDRE, is mediated by Sp1, NF-Y transcription factors and by post-transcriptional 
mechanisms. Moreover, vitamin D modulates the expression of proliferation-related 
genes such as c-myc, c-fos and c-jun (Scaglione-Sewell et al., 2000). 
 Vitamin D also exerts anti-cancer effects by interfering the synthesis of growth 
factors and cytokines and/or modulating their signaling pathways. Normal colonic 
epithelial proliferation is inhibited by TGF-β signaling. As previously discussed, 
disruption of TGF-β signaling is involved in CRC malignant progression. In some 
models, vitamin D can restore sensitivity to TGF-β by inducing the expression of the 
TGF-β1 receptor (Chen et al., 2002).  
In addition to the growth inhibitory effects, vitamin D induces the differentiation 
of colon cancer cells. In Caco-2 and HT-29 cells, treatment with 1α,25(OH)2D3 
enhances morphological differentiation parameters, such as the number of desmosomes, 
intermediate filaments and microvilli length and density. Moreover, 1α,25(OH)2D3 
significantly increases the expression and activity of alkaline phosphatase, a marker of 
colonic differentiation. In SW480 colon cancer cells, the activation of VDR by 
1α,25(OH)2D3 produces dramatic changes in adherent junctions integrity, increases 
differentiation and reduces oncogenic cell signaling. More specifically, 1α,25(OH)2D3 
induces the expression of E-cadherin, and other adhesion proteins (occludin, zonula 
ocludens (ZO-1 and ZO-2), and vinculin), the translocation of β-catenin, plakoglobin, 
and ZO-1 from the nucleus to the plasma membrane, and the transrepression of Wnt/β-
catenin/Tcf signaling (Palmer et al., 2001). The Wnt signaling pathway regulates gene 
expression, cell adhesion, and tissue development. Wnt ligands or mutations in key 
regulators of the Wnt-pathway, such as APC and β-catenin (early genetic alterations in 
CRC) ultimately result in the nuclear accumulation of β-catenin, where it binds to the 
TCF/LEF family of transcription factors, leading to the regulation of Wnt-target genes 
(PPARδ, Tcf-1, matrilysin, cyclin D1, and CD44). Induction of these genes has 
dramatic effects on cell and tissue development, and oncogenesis. Treatment with 
1α,25(OH)2D3 of colon cancer cells represses Wnt target genes, thus contributing to 
maintain the differentiated phenotype and growth arrest. The direct interaction of 
activated VDR with β-catenin in the nucleus suggests that competitive displacement of 
β-catenin from TCF sites may account for the repressive activity of 1α,25(OH)2D3 
(FIG.1). 
The anti-cancer activity of vitamin D in colon cancer is also linked to apoptosis 
induction (FIG.2). In certain cells, apoptosis occurs subsequent to the induction of 
differentiation, as suggested by the increase in alkaline phosphatase activity. Although 
the underlying mechanisms remain unclear, it has been reported that the induction of 
apoptosis by vitamin D is associated with the up-regulation of the pro-apoptotic protein 
bak and the down-regulation of the anti-apoptotic protein bcl-2 (Diaz et al., 2000). The 
effects of vitamin D on the expression of other Bcl-2 family members, such as BAX and 
BCL-XL are controversial, and are cell-type dependent.  
Interestingly, it has been found that VDR is a receptor for the lithocholic acid 
(LCA), a secondary bile acid. Fat-rich diets contain high levels of LCA, which 
generates DNA damage in normal colon cells and, therefore, increases the risk to 
develop CRC. Activation of VDR by either LCA or vitamin D up-regulates CYP3A, 
SULT2A1, and MRP3 gene transcription; these proteins are involved  in the 
detoxification of LCA in the liver and intestine. Thus, VDR, behaving as an intestinal 
bile acid sensor, can protect colon cells from the deleterious effect of LCA and prevent 
the development of CRC (Makishima et al., 2002).  
 
3.2. VITAMIN D ANALOGS: PROMISING THERAPEUTIC OPTIONS. 
The clinical use of 1α,25(OH)2D3 and 1α,25(OH)2D3 analogs for the treatment 
of malignancies is still in its infancy. Despite the positive results obtained with the 
1α,25(OH)2D3 analogs when analyzed with in vitro and in vivo rodents models of colon 
carcinogenesis, they have proved to be poorly efficient in clinical assays. A major 
hindrance for the translation from basic to applied research depends on the induction of 
hypercalcemia by with most currently available VDR ligands. In this regard, the vitamin 
D analog EB1089 was well tolerated in a Phase I clinical trial, including patients with 
advanced breast and colorectal cancers; however, clear tumor suppressive effects were 
not observed (Gulliford et al., 1998). Therefore, a clinical demand is to identify new 
VDR ligands exhibiting improved therapeutic impact, and to establish new strategies for 
CRC chemoprevention based on VDR ligands. The combination of vitamin D analogs 
with other anti-tumor agents (i.e. chemotherapeutic drugs, epigenetic drugs, etc.) may 
result in enhanced anti-cancer efficiency, as is the case in leukemia treatment, where 
combination therapy is successful. A big effort is being made to develop novel synthetic 
VDR ligands that dissociate the beneficial activities from the undesired hypercalcemic 
effects. For instance, VDR ligands that function in a cell- and/or gene-selective manner 
have been recently developed, which in vivo show a striking dissociation of biological 
efficiency from calcium liability (Ma et al., 2006). Interestingly, new 1α,25(OH)2D3 
analogs are able to repress AP-1 (c-Jun/c-Fos)-dependent transcription, but are impaired 
for the transcription of promoters containing VDRE (Castillo et al., 2006). Since the 
AP-1 complex regulates the expression of genes involved in oncogenic transformation 
and cellular proliferation, these compounds become potential therapeutic weapons 
against cancer, with the additional advantage of excluding the deleterious side effects 
derived from the activation of VDRE-containing genes. It has been postulated that the 
selective activity of these VDR ligands relies on the induction of distinct 
conformational changes in the receptor, which may result in recruitment of different 
cofactors from those required for the regulation of target gene expression. In agreement 
with this idea, it has been shown that activated VDR binds β-catenin under conditions in 
which other co-activators are unable to (Shah et al., 2006). Since aberrant Wnt/β-
catenin signaling plays an important role in the development of CRC, it would be 
important for the future development of vitamin D analogs to determine their ability to 
regulate not only VDR activity but also VDR/β-catenin interaction and β-catenin 
signaling. These molecular criteria should be taken into account in order to develop 
novel VDR ligands with anticipated anti-cancer potential. 
 
4. CONCLUSIONS AND PERSPECTIVES  
 
The need to further explore the therapeutic and prevention potential of vitamin 
D and its non-calcemic analogs in colorectal cancer is strongly support by the abundant 
evidence provided by epidemiological, experimental and clinical studies. However, 
further studies are required in order to better define the signal transduction pathways 
and the target genes involved in the anti-cancer activity of vitamin D. Additionally, it is 
relevant to analyze the molecular mechanisms underlying the low sensitivity or 
resistance of colon cancer cells to the anti-cancer effect of vitamin D. In this context, it 
is necessary to identify genetic and epigenetic alterations in the key players of vitamin 
D signaling, accounting for vitamin D-resistance. Combined treatments of VDR ligands 
with drugs targeting different signaling pathways could restore vitamin D sensitivity, or 
increase its anti-cancer effect. Finally, the synthesis and characterization of novel VDR 
ligands with improved therapeutic indices and reduced side effects will become a 
priority research area, hopefully providing new tools in the management of colorectal 
cancer. 
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FIGURE LEGENDS 
 
FIG.1. Molecular mechanisms of vitamin D-induced differentiation. In normal cells, the 
level of free β-catenin (β-cat), which is in equilibrium with β-catenin at adherent 
junctions, is regulated by degradation via the proteasome. Free β-catenin is recruited to 
a complex with APC, axin and glycogen synthase kinase 3β (GSK3β) in the cytoplasm, 
and phosphorylation of β-catenin by GSK3β promotes its degradation by the 
proteasome. In SW480 colon cancer cells, as a result of APC gene mutations and low E-
cadherin levels, β-catenin accumulates in the cytoplasm and is free to enter the nucleus, 
where it induces Tcf-dependent transcription (left). In the presence of vitamin D (right), 
the transcription of Tcf- target genes is repressed. Activated VDR associates with β-
catenin, displacing β-catenin from Tcf-containing promoters. In this context, β-catenin 
might potentially function as a co-activator of certain VDR-target genes. Vitamin D 
reduces the nuclear levels of β-catenin by increasing its interaction with E-cadherin, 
which in turn is up-regulated by vitamin D treatment. V, vitamin D receptor; X, retinoid 
X receptor; VDRE, vitamin D response element; α-cat, α-catenin. 
 
 
FIG2. Molecular basis of vitamin D-induced apoptosis. 1α,25-dihydroxy vitamin D3 
[1α,25-(OH)2D3] up-regulates the pro-apoptotic protein bak and down-regulates the 
anti-apoptotic protein bcl-2. Pro-apoptotic and anti-apoptotic bcl-2 family members 
regulate the permeability of the mitochondria outer membrane and, hence, the release of 
cytochrome c and other pro-apoptotic factors. Cytochrome c associates with APAF-1 
and pro-caspase 9 to form the apoptosome, which triggers caspase 3 activation, 
inducing the cleavage of different substrates in apoptotic cells. Another bcl-2-family 
member, BID, when cleaved by caspase 8 (tBID), translocates to the mitochondria 
membrane and triggers the mitochondria-dependent or intrinsic death pathway. BID 
connects the extrinsic (death-receptor mediated cell death pathway) and the intrinsic 
death pathways. In prostate cancer cells, 1α,25-(OH)2D3 induces the down-regulation of 
inhibitor of apoptosis proteins (IAP). APAF-1, apoptotic protease activating factor-1; 
BAK, Bcl-2-antagonist killer ; BAX, Bcl-2-associated X protein; tBID, truncated BH3-
interacting domain death agonist; BCL-2, B-cell CLL/lymphoma-2 protein; BCL-XL, 
BCL2-related protein, long isoform; FADD, FAS-associated death domain. 
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